{
    "clinical_study": {
        "@rank": "148026", 
        "arm_group": [
            {
                "arm_group_label": "1 combination tablet EC905", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2: solifenacin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "3: tamsulosin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to assess the amount of drug in the blood of young to middle aged, healthy, male\n      subjects after they received the final formulation of EC905 compared to solifenacin\n      (Vesicare\u00ae) and tamsulosin OCAS (Omnic OCAS\u00ae).\n\n      Subjects are given a single dose of the combination tablet EC905, Vesicare\u00ae and Omnic OCAS\u00ae\n      in 3 separate periods."
        }, 
        "brief_title": "A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin", 
        "completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "EC905", 
            "Pharmacokinetics", 
            "Healthy Subjects"
        ], 
        "detailed_description": {
            "textblock": "The subjects are randomized to one of 6 treatment sequence groups.\n\n      Subjects are admitted to the clinical unit on Day -1 for pre-dose assessments. They remain\n      in the clinic for two periods of 11 days and one period of 14 days.\n\n      After randomization the subjects receive a single dose treatment on Day 1 followed by blood\n      sampling for pharmacokinetic (PK) assessment. For both EC905 and Vesicare\u00ae, blood sampling\n      continues for 10 days after dosing; for Omnic OCAS\u00ae, it continues for 3 days after dosing.\n\n      Each period is separated by a wash-out period of at least 4 day, and subjects are checked\n      for eligibility again one day prior to the start of a new dosing day.\n\n      Vital signs, safety ECG measurements, safety laboratory assessments, adverse events and\n      concomitant medications are monitored throughout the investigational period.\n\n      A blood sample is drawn for CYP2D6 genotyping, in order to evaluate the effect of the CYP2D6\n      genotype on the PK of tamsulosin.\n\n      Subjects return for an End of Study Visit (ESV) 7 days after the last on-site period, or\n      after withdrawal."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index between 18.5 and 30.0 kg/m2, inclusive\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to solifenacin, tamsulosin, EC905, Vesicare,\n             Omnic OCAS or any of the components of the formulations used.\n\n          -  Any of the contraindications or precautions for use as mentioned in the applicable\n             sections of the SPC's of tamsulosin or solifenacin.\n\n          -  Use of grapefruit (more than 3 x 200 ml) or marmalade (more than three times) in the\n             week prior to admission to the Clinical Unit, as reported by the subject.\n\n          -  Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953887", 
            "org_study_id": "905-CL-072", 
            "secondary_id": "2009-015618-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 combination tablet EC905", 
                "description": "Oral", 
                "intervention_name": "EC905", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2: solifenacin", 
                "description": "oral", 
                "intervention_name": "solifenacin", 
                "intervention_type": "Drug", 
                "other_name": "Vesicare\u00ae"
            }, 
            {
                "arm_group_label": "3: tamsulosin", 
                "description": "oral", 
                "intervention_name": "tamsulosin", 
                "intervention_type": "Drug", 
                "other_name": "Omnic OCAS\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamsulosin", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase I", 
            "Final formulation EC905", 
            "Solifenacin succinate", 
            "Tamsulosin HCl", 
            "Marketed drugs"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "Link to Results on JAPIC", 
            "url": "http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1060"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "HA1 3UJ"
                }, 
                "name": "Parexel"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare\u00ae) and Tamsulosin OCAS (Omnic OCAS\u00ae)", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Study Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUClast (Area under the curve until last sample taken), Cmax (Maximum concentration)", 
                "measure": "The Pharmacokinetics (PK) of solifenacin after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare\u00ae and Omnic OCAS\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Predose to Day 10 after dosing (22 times)"
            }, 
            {
                "description": "AUClast (Area under the curve until last sample taken), Cmax (Maximum concentration)", 
                "measure": "The Pharmacokinetics (PK) of tamsulosin HCl after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare\u00ae and Omnic OCAS\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Predose to Day 10 after dosing (22 times)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUCinf (AUC extrapolated until infinity), t1/2 (Apparent terminal elimination half-life), tmax (Time to attain Cmax), CL/F (Apparent total body plasma clearance), Vz/F (Apparent volume of distribution)", 
                "measure": "The PK of solifenacin and tamsulosin HCl after a single dose of the final formulation of the combination tablet EC905 with a single dose of Vesicare\u00ae and Omnic OCAS\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Predose to Day 10 after dosing (22 times)"
            }, 
            {
                "description": "Adverse events, clinical laboratory tests, vital signs, Electrocardiogram (ECG), physical examination", 
                "measure": "Safety and tolerability of single doses of the final formulation combined EC905, marketed Vesicare\u00ae and marketed Omnic OCAS\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Screening to End of Study Visit (at least 7 days after the last on site period (treatment and PK sampling), or after withdrawal.)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}